Evolution of Metastases in Space and Time under Immune Selection

Cell

Volumn 175, Issue 3, 2018, Pages 751-765.e16

  Angelova, Mihaela ^a   Mlecnik, Bernhard ^a,b   Vasaturo, Angela ^a   Bindea, Gabriela ^a   Fredriksen, Tessa ^a   Lafontaine, Lucie ^a   Buttard, Bénédicte ^a   Morgand, Erwan ^a   Bruni, Daniela ^a   Jouret Mourin, Anne ^c   Hubert, Catherine ^c   Kartheuser, Alex ^c   Humblet, Yves ^c   Ceccarelli, Michele ^d,e   Syed, Najeeb ^f   Marincola, Francesco M ^f,g   Bedognetti, Davide ^f   Van den Eynde, Marc ^a,c   Galon, Jérôme ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b Inovarion   (France)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d UNIVERSITY OF SANNIO   (Italy)

^e Grande Ospedale Metropolitano   (Italy)

^f SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^g Refuge Biotechnologies Inc   (United States)

Author keywords

clonal; heterogeneity; immunoediting; immunoscore; immunotherapy; metastasis; microenvironment; mutations; recurrence; T cells

Indexed keywords

KI 67 ANTIGEN;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE BURDEN; EVOLUTION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNE SELECTION; IMMUNITY; IMMUNOEDITING; IMMUNOSURVEILLANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MOLECULAR CLONING; PREDICTION; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR EVOLUTION; TUMOR MICROENVIRONMENT;

EID: 85055072341     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2018.09.018     Document Type: Article

References (37)

1. Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A.C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39 (2013), 782–795.
2. Bolotin, D.A., Poslavsky, S., Mitrophanov, I., Shugay, M., Mamedov, I.Z., Putintseva, E.V., Chudakov, D.M., MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods 12 (2015), 380–381.
3. Caswell, D.R., Swanton, C., The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med., 15, 2017, 133.
4. Davoli, T., Uno, H., Wooten, E.C., Elledge, S.J., Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science, 355, 2017, 10.1126/science.aaf8399 Published online January 20, 2017.
5. Fearon, E.R., Vogelstein, B., A genetic model for colorectal tumorigenesis. Cell 61 (1990), 759–767.
6. Finn, O.J., Cancer immunology. N. Engl. J. Med. 358 (2008), 2704–2715.
7. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
8. Gerlinger, M., Rowan, A.J., Horswell, S., Math, M., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 (2012), 883–892.
9. Germano, G., Lamba, S., Rospo, G., Barault, L., Magrì, A., Maione, F., Russo, M., Crisafulli, G., Bartolini, A., Lerda, G., et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552 (2017), 116–120.
10. Gerstung, M., Eriksson, N., Lin, J., Vogelstein, B., Beerenwinkel, N., The temporal order of genetic and pathway alterations in tumorigenesis. PLoS ONE, 6, 2011, e27136.
11. Hunter, K.W., Amin, R., Deasy, S., Ha, N.H., Wakefield, L., Genetic insights into the morass of metastatic heterogeneity. Nat. Rev. Cancer 18 (2018), 211–223.
12. Jimenez-Sanchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H.A., Gill, M.B., Park, K.J., Zivanovic, O., Konner, J., et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170 (2017), 927–938.
13. Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth, M.J., Schreiber, R.D., Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 (2007), 903–907.
14. Labiano, S., Palazon, A., Melero, I., Immune response regulation in the tumor microenvironment by hypoxia. Semin. Oncol. 42 (2015), 378–386.
15. Langley, R.R., Fidler, I.J., Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr. Rev. 28 (2007), 297–321.
16. Lloyd, M.C., Cunningham, J.J., Bui, M.M., Gillies, R.J., Brown, J.S., Gatenby, R.A., Darwinian dynamics of intratumoral heterogeneity: Not solely random mutations but also variable environmental selection forces. Cancer Res. 76 (2016), 3136–3144.
17. Matsushita, H., Vesely, M.D., Koboldt, D.C., Rickert, C.G., Uppaluri, R., Magrini, V.J., Arthur, C.D., White, J.M., Chen, Y.S., Shea, L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482 (2012), 400–404.
18. McGranahan, N., Furness, A.J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., Jamal-Hanjani, M., Wilson, G.A., Birkbak, N.J., Hiley, C.T., et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351 (2016), 1463–1469.
19. McGranahan, N., Rosenthal, R., Hiley, C.T., Rowan, A.J., Watkins, T.B.K., Wilson, G.A., Birkbak, N.J., Veeriah, S., Van Loo, P., Herrero, J., et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171 (2017), 1259–1271.
20. Mlecnik, B., Bindea, G., Angell, H.K., Sasso, M.S., Obenauf, A.C., Fredriksen, T., Lafontaine, L., Bilocq, A.M., Kirilovsky, A., Tosolini, M., et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci. Transl. Med., 6, 2014, 228ra37.
21. Mlecnik, B., Bindea, G., Angell, H.K., Maby, P., Angelova, M., Tougeron, D., Church, S.E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44 (2016), 698–711.
22. Mlecnik, B., Bindea, G., Kirilovsky, A., Angell, H.K., Obenauf, A.C., Tosolini, M., Church, S.E., Maby, P., Vasaturo, A., Angelova, M., et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci. Transl. Med., 8, 2016, 327ra26.
23. Mlecnik, B., Van den Eynde, M., Bindea, G., Church, S.E., Vasaturo, A., Fredriksen, T., Lafontaine, L., Haicheur, N., Marliot, F., Debetancourt, D., et al. Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival. J. Natl. Cancer Inst., 110, 2018, 10.1093/jnci/djx123 Published online January 1, 2018.
24. Murugaesu, N., Wilson, G.A., Birkbak, N.J., Watkins, T., McGranahan, N., Kumar, S., Abbassi-Ghadi, N., Salm, M., Mitter, R., Horswell, S., et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov. 5 (2015), 821–831.
25. Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353 (2005), 2654–2666.
26. Prendergast, G.C., Jaffee, E.M., Cancer immunologists and cancer biologists: Why we didn't talk then but need to now. Cancer Res. 67 (2007), 3500–3504.
27. Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., Hacohen, N., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
28. Roth, A., Khattra, J., Yap, D., Wan, A., Laks, E., Biele, J., Ha, G., Aparicio, S., Bouchard-Côté, A., Shah, S.P., PyClone: Statistical inference of clonal population structure in cancer. Nat. Methods 11 (2014), 396–398.
29. Schreiber, R.D., Old, L.J., Smyth, M.J., Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331 (2011), 1565–1570.
30. Schwarz, R.F., Trinh, A., Sipos, B., Brenton, J.D., Goldman, N., Markowetz, F., Phylogenetic quantification of intra-tumour heterogeneity. PLoS Comput. Biol., 10, 2014, e1003535.
31. Shukla, S.A., Rooney, M.S., Rajasagi, M., Tiao, G., Dixon, P.M., Lawrence, M.S., Stevens, J., Lane, W.J., Dellagatta, J.L., Steelman, S., et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33 (2015), 1152–1158.
32. Sottoriva, A., Kang, H., Ma, Z., Graham, T.A., Salomon, M.P., Zhao, J., Marjoram, P., Siegmund, K., Press, M.F., Shibata, D., Curtis, C., A Big Bang model of human colorectal tumor growth. Nat. Genet. 47 (2015), 209–216.
33. Talevich, E., Shain, A.H., Botton, T., Bastian, B.C., CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol, 12, 2016, e1004873.
34. Turajlic, S., Swanton, C., Metastasis as an evolutionary process. Science 352 (2016), 169–175.
35. Wang, Y., Waters, J., Leung, M.L., Unruh, A., Roh, W., Shi, X., Chen, K., Scheet, P., Vattathil, S., Liang, H., et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512 (2014), 155–160.
36. Williams, M.J., Werner, B., Barnes, C.P., Graham, T.A., Sottoriva, A., Identification of neutral tumor evolution across cancer types. Nat Genet. 48 (2016), 238–244.
37. Zhang, A.W., McPherson, A., Milne, K., Kroeger, D.R., Hamilton, P.T., Miranda, A., Funnell, T., Little, N., de Souza, C.P.E., Laan, S., et al. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell 173 (2018), 1755–1769.